- Home
- SFL vs MNKD Comparison
SFL vs MNKD Comparison
Compare SFL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- MNKD
- Stock Information
- Founded
- SFL 2003
- MNKD 1991
- Country
- SFL Bermuda
- MNKD United States
- Employees
- SFL N/A
- MNKD N/A
- Industry
- SFL Marine Transportation
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- MNKD Health Care
- Exchange
- SFL Nasdaq
- MNKD Nasdaq
- Market Cap
- SFL 1.1B
- MNKD 1.2B
- IPO Year
- SFL N/A
- MNKD 2004
- Fundamental
- Price
- SFL $8.09
- MNKD $5.39
- Analyst Decision
- SFL Strong Buy
- MNKD Strong Buy
- Analyst Count
- SFL 1
- MNKD 5
- Target Price
- SFL $13.00
- MNKD $10.80
- AVG Volume (30 Days)
- SFL 1.3M
- MNKD 5.8M
- Earning Date
- SFL 11-05-2025
- MNKD 11-06-2025
- Dividend Yield
- SFL 13.33%
- MNKD N/A
- EPS Growth
- SFL N/A
- MNKD 149.32
- EPS
- SFL 0.26
- MNKD 0.11
- Revenue
- SFL $852,528,000.00
- MNKD $301,736,000.00
- Revenue This Year
- SFL N/A
- MNKD $16.36
- Revenue Next Year
- SFL $3.16
- MNKD $20.34
- P/E Ratio
- SFL $30.89
- MNKD $50.42
- Revenue Growth
- SFL 3.21
- MNKD 21.48
- 52 Week Low
- SFL $6.78
- MNKD $3.38
- 52 Week High
- SFL $11.85
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- SFL 42.14
- MNKD 63.64
- Support Level
- SFL $7.93
- MNKD $5.25
- Resistance Level
- SFL $8.31
- MNKD $5.77
- Average True Range (ATR)
- SFL 0.16
- MNKD 0.29
- MACD
- SFL 0.01
- MNKD -0.01
- Stochastic Oscillator
- SFL 35.56
- MNKD 54.75
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.